Asset
IVOSIDENIB
AGIOS PHARMACEUTICALS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03282513 | phase1 | completed | 2017-09-26 | 2018-03-31 | Agios Pharmaceuticals, Inc. | A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function |
| NCT03071770 | phase1 | completed | 2017-03-31 | 2017-05-09 | Agios Pharmaceuticals, Inc. | Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects |
FDA applications (0)
This company has no applications containing this asset.